Highest-materiality recent filing
Medtronic discloses unauthorized access to corporate IT systems; no patient or product impact found
Unauthorized third party accessed data in certain Medtronic corporate IT systems; incident discovered April 24, 2026.
Medtronic cuts FY2026 EPS guidance on MiniMed charges; FDA clears MiniMed Flex pump
FDA cleared MiniMed Flex insulin pump several months earlier than expected; smartphone-controlled.
GAAP diluted EPS $0.89; non-GAAP diluted EPS $1.36, three cents above Q3 guidance mid-point.
Medtronic Q2 FY26: Revenue $9.0B (+5.5% organic), non-GAAP EPS $1.36 (+8%); raises FY26 guidance
Q2 organic revenue growth 5.5% (beat guidance midpoint by 75 bps); GAAP EPS $1.07 (+8%), non-GAAP EPS $1.36 (+8%).
Medtronic Q1 revenue $8.58B (+4.8% organic); raises FY26 EPS; adds 2 directors, forms new committees
Q1 GAAP EPS $0.81; non-GAAP EPS $1.26 (+2%), revenue $8.58B, organic growth 4.8%.
Medtronic Q4 EPS $1.62 non-GAAP (+11%); to spin off Diabetes; dividend raised to $0.71
Q4 FY25 revenue $8.93B (+5.4% organic); non-GAAP EPS $1.62 (+11% as reported, +16% constant currency).
Brett Wall will be departing from his position as Executive Vice President and President, Neuroscience Portfolio
Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will be assuming the role of Executive Vice President and President, Neuroscience Portfolio, effective June 1, 2026.
On June 18, 2025, the Board of Directors (Board) of Medtronic plc (Company) increased the size of the Board from 10 to 11 and appointed Dr. Joon Lee as a new director of the Company, in each case effective as of June 18, 2025.
Skip Kiil would be assuming the role of EVP and President, Cardiovascular Portfolio
Sean Salmon would be departing from his position as EVP and President, Cardiovascular Portfolio
Max materiality 0.85 · Median 0.57 · Most common event earnings